Sanat Chattopadhyay - Merck President
MRCK34 Stock | BRL 82.64 0.61 0.74% |
President
Mr. Sanat Chattopadhyay is the Executive Vice President and President Merck Manufacturing Division of the Company. He joined Merck in 2009 and currently serves as senior vice president of Global Manufacturing Operations . He was instrumental in transforming Merck Vaccines manufacturing and supply to grow and globalize the company vaccines business. Chattopadhyay also played a key part in leading the company launch of KEYTRUDA in record time by mobilizing a crossdivisional effort to overcome commercialization and supply constraints. since 2016.
Age | 58 |
Tenure | 8 years |
Phone | 908 740 4000 |
Web | https://www.merck.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Brian Durkin | AbbVie Inc | 57 | |
Chirfi Guindo | Biogen Inc | 52 | |
William Chase | AbbVie Inc | 50 | |
Sanjay Jariwala | Biogen Inc | N/A | |
Joseph Caldarella | Bristol Myers Squibb | 61 | |
Nicholas Donoghoe | AbbVie Inc | 37 | |
Alfred Sandrock | Biogen Inc | 60 | |
Christopher Boerner | Bristol Myers Squibb | 52 | |
Azita SalekiGerhardt | AbbVie Inc | 60 | |
JeanPaul Kress | Biogen Inc | 50 | |
Laura Hamill | Gilead Sciences | 53 | |
Andrew Cheng | Gilead Sciences | N/A | |
Carlos Alban | AbbVie Inc | 55 | |
Martin Silverstein | Gilead Sciences | 48 | |
Robert Michael | AbbVie Inc | 53 | |
Gregory Covino | Biogen Inc | 51 | |
Anne Nielsen | Bristol Myers Squibb | 55 | |
Kathleen Watson | Gilead Sciences | N/A | |
Ginger Gregory | Biogen Inc | 55 | |
Laura Schumacher | AbbVie Inc | 60 | |
Catherine Steele | Biogen Inc | N/A |
Management Performance
Return On Equity | 0.35 | |||
Return On Asset | 0.13 |
Merck Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director | ||
Craig Thompson, Independent Director | ||
Cristal Downing, Ex Officer | ||
Jennifer Zachary, General Counsel | ||
Rochelle Lazarus, Independent Director | ||
Wendell Weeks, Independent Director | ||
Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
Paul Rothman, Director | ||
Mary Coe, Director | ||
Adele Ambrose, Senior Vice President Chief Communications Officer | ||
Caroline Litchfield, Ex CFO | ||
Joseph Romanelli, IR Contact Officer | ||
Mirian GraddickWeir, Executive Vice President - Human Resources | ||
Peter Wendell, Independent Director | ||
John Noseworthy, Independent Director | ||
Jennifer Mauer, VP Communications | ||
Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health | ||
Leslie Brun, Independent Director | ||
Inge Thulin, Director | ||
Pamela Craig, Director | ||
Patricia Russo, Independent Director | ||
David Williams, Ex Officer | ||
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
Lisa LeCointeCephas, VP Officer | ||
Robert Davis, CFO and Executive VP | ||
Robert Kidder, Independent Director | ||
Thomas Cech, Independent Director | ||
Michael Nally, Chief Marketing Officer | ||
Peter Dannenbaum, VP Relations | ||
Clark Golestani, CIO and Executive VP | ||
William Harrison, Lead Independent Director | ||
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
Steven Mizell, Chief Human Resource Officer | ||
Jim Scholefield, Chief Information and Digital Officer | ||
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
Adam Schechter, President of Global Human Health and Executive VP | ||
Carlos Represas, Independent Director | ||
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
Kenneth Frazier, Chairman, CEO and Pres | ||
Frank Clyburn, Chief Commercial Officer | ||
Robert JD, CEO Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.35 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.24 % | |||
Operating Margin | 0.38 % | |||
Current Valuation | 1.6 T | |||
Shares Outstanding | 20.28 B | |||
Price To Earning | 96.57 X | |||
Price To Book | 6.31 X | |||
Price To Sales | 25.29 X | |||
Revenue | 59.28 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Merck information on this page should be used as a complementary analysis to other Merck's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |